产品名称
sPLA2-IIA Inhibitor I, The sPLA2-IIA Inhibitor I controls the biological activity of sPLA2-IIA. This small molecule/inhibitor is primarily used for Cell Signaling applications.
assay
≥95% (HPLC)
form
lyophilized solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
color
white
solubility
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: no
Primary Target
sPLA2-IIA (human type IIA secreted phospholipase A2
sPLA2-IIA (human type IIA secreted phospholipase A2
Product does not compete with ATP.
Reversible: no
Target IC50: 12.8 µM against sPLA2-IIA (human type IIA secreted phospholipase A2
Disclaimer
Toxicity: Standard Handling (A)
General description
A highly hydrophobic cyclic pentapeptide that selectively binds and acts as a potent inhibitor of sPLA2-IIA (human type IIA secreted phospholipase A2; IC50 = 12.8 μM). Shown to effectively block sPLA2-IIA-induced PGE2 production at 100 nM in human rheumatoid synoviocytes and is non-toxic at doses up to 10 μM. Does not have any significant effect on the activities of porcine sPLA2-IB, Naja naja sPLA2-IB, or Crotalus durissus sPLA2-IIA even at 10 μM concentration.
Other Notes
Church, W.B., et al. 2001. J. Biol. Chem.276, 33156.
cyclic(2-NaphthylAla-Leu-Ser-2-NaphthylAla-Arg)•TFA
Packaging
Packaged under inert gas
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Julien Pothlichet et al.
Frontiers in immunology, 13, 824746-824746 (2022-04-09)
The origin of the impaired CD4 T-cell response and immunodeficiency of HIV-infected patients is still only partially understood. We recently demonstrated that PLA2G1B phospholipase synergizes with the HIV gp41 envelope protein in HIV viremic plasma to induce large abnormal membrane
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持